The avocado is packed with a nutritious punch, as it contains vitamins K, E, C, and B, along with potassium and other nutrients that are necessary for good health. A new study finds that avocados also includes an ingredient that may effectively battle one form of cancer, as it has been proven that a compound derived from the tasty avocado can target and kill the stem cells of acute myeloid leukemia.
Avocados have won over many people, including dieticians, in recent years, as they’re high in fiber, protein, and healthy fats that promote good cardiac function, and not quite long, fighting a specific type of leukemia.
A study from the University of Waterloo in Ontario, Canada that was published in the journal Cancer Research, looks at the effects of avocado on acute myeloid leukemia (AML), which is a form of bone cancer.
This form of cancer is deadly and particularly common among elderly people. The results can be deadly, and the five-year survival rate for acute myeloid leukemia is only 25%.
Acute myeloid leukemia develops in the bone marrow and can quickly spread to the blood, making it a very dangerous form of cancer. It is often referred to as AML and starts in the soft inner part of certain bones, where new blood cells are made.
In most cases, acute myeloid leukemia quickly moves into the blood and in some cases, it spreads from the blood to other parts of the body. This medical issue primarily affects older people, and is driven by the stem cell, which both causes the disease to develop in the first case and then is responsible for relapse.
Dr. Paul Spagnuolo, a professor at the University of Waterloo, claimed that they’ve identified a novel molecule that comes from avocados that has potent toxicity against leukemia and leukemia stem cells. Spagnuolo and his lab have conducted many rounds of testing to understand the molecular workings of this new compound, avocatin B, and confirmed that it selectively aims for and destroys unhealthy stem cells, leaving healthy ones unharmed.
Through a partnership with the Centre for Commercialization of Regenerative Medicine, Spagnuolo has filed a patent application for avocatin B with the hopes of eventually taking the compound into clinical trials.
Some chemotherapy drugs are good at removing leukemia from patients, but they don’t remove the stem cells, and though avocatin B is still years away from being prescribed by oncologists, some of the most potent chemotherapy drugs used today have been similarly derived from plants.
Spagnuolo has backed up his claims by enumerating how his lab’s research has been published in one of the best scientific journals, presented at the annual meeting of the American Society of Hematology, and funded by a prestigious non-profit organization.